Stryker Corporation's ABG II and Rejuvenate hip stem litigation has largely concluded following a confirmed settlement program announced in November 2014. The company paid out an estimated $1.4 billion combined to resolve claims related to corrosion and fretting at the modular neck junction, with average...
Stryker Corp. reported second-quarter 2026 results showing revenue growth of 9.4 percent to USD 6.59 billion, with adjusted earnings per share reaching USD 3.69, beating the consensus estimate by USD 0.20. The company's stock closed at USD 275.09 on September 22, 2026, reflecting a modest...
Stryker Corp. shares declined by 1.63% to close at USD 280.13 on September 17, 2026, following a downgrade from analyst firm Canaccord Genuity. The firm lowered its price target for the medical device manufacturer from USD 400 to USD 385, citing ongoing manufacturing problems as...
Stryker Corporation (SYK) faces a valuation premium compared to rivals like Boston Scientific, trading at 18.8 times operating income versus 14.3x for the competitor. Despite this higher cost, Stryker maintains a larger market capitalization of approximately $106 billion and boasts an operating margin of 21.7%,...
Stryker Corporation (NYSE: SYK) saw its stock price decline by more than 10% over the past five days as the company acknowledged ongoing supply disruptions affecting its operations. During a presentation at Wells Fargo's healthcare conference, CFO Preston Wells confirmed that the orthopedic and surgical...
